Get the Stockscreener App
3.37
4.26%
-0.15
After Hours:
3.37
Recursion Pharmaceuticals Inc stock is traded at $3.37, with a volume of 13.37M.
It is down -4.26% in the last 24 hours and up +8.36% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.52
Open:
$3.52
24h Volume:
13.37M
Relative Volume:
0.87
Market Cap:
$1.79B
Revenue:
$74.68M
Net Income/Loss:
$-644.76M
P/E Ratio:
-2.2726
EPS:
-1.4829
Net Cash Flow:
$-380.44M
1W Performance:
-1.17%
1M Performance:
+8.36%
6M Performance:
-32.06%
1Y Performance:
-29.13%
1-Day Range:
$3.32
$3.5579
1-Week Range:
$3.20
$3.59
52-Week Range:
$2.80
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.37 | 1.87B | 74.68M | -644.76M | -380.44M | -1.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion earnings in focus as AI drug platform faces revenue test - Investing.com
Blake Borgeson sells 200,000 Class A shares (RXRX) under Rule 144 - Stock Titan
Recursion Pharmaceuticals Stock Short Interest Rises to 35.49% - Quiver Quantitative
Recursion Pharmaceuticals Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat - Sahm
Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings? - Yahoo Finance
Does Recursion’s 2026 Update And Board Shift Reframe Its AI Drug Discovery Ambitions For RXRX? - Sahm
What Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny Stock - Insider Monkey
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Investor Sentiment Splits On Future Prospects - Sahm
Recursion Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Recursion Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings - TechStock²
Recursion Pharmaceuticals : 2026 Proxy Statement - marketscreener.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co. - MarketBeat
Recursion Pharmaceuticals Announces Planned Board Leadership Transition - TipRanks
Recursion Pharmaceuticals | DEFA14A: Others - Moomoo
[ARS] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion (RXRX) outlines 2026 virtual meeting, board elections and pay votes - Stock Titan
Recursion founder exits board in June but stays on as adviser - Stock Titan
Recursion Pharmaceuticals | 8-K: Current report - Moomoo
Founder Chris Gibson to exit Recursion Pharmaceuticals (NASDAQ: RXRX) board - Stock Titan
Recursion Announces Board Transition - marketscreener.com
MSN Money - MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 - marketscreener.com
Recursion opens May 6 earnings call to public questions online - Stock Titan
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' (NASDAQ:RXRX) - Seeking Alpha
Recursion names Vicki Goodman as CMO - MSN
Recursion Pharmaceuticals May Be Losing Ground To Its Peers (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals Projects Massive Growth Amid Clinical Success - HarianBasis.co
Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities - Insider Monkey
Recursion names Najat Khan CEO, succeeding co-founder Chris Gibson; stock down - MSN
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - MSN
Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast - Yahoo Finance
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
10 Most Shorted Penny Stocks to Buy - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention - Yahoo Finance
Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com India
Recursion Pharmaceuticals director Gibson sells $144,400 in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan
ETFs Investing in Recursion Pharmaceuticals, Inc. Class A Stocks - TradingView
AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - simplywall.st
Christopher Gibson sells Class A shares (NASDAQ: RXRX) in four filings - Stock Titan
Recursion Pharmaceuticals Uses AI to Accelerate Drug Development - HarianBasis.co
Recursion Pharmaceuticals Inc (RXRX): Is AI Strategy Working? - Insider Monkey
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):